June 13, 2022
Addressing the challenges of chimeric antigen receptor-T cell therapy
Article by Marla Broadfoot Chimeric antigen receptor-T cell therapy (CAR-T cell therapy) — a type of immunotherapy that reprograms a patient’s T cells to recognize and destroy cancer cells — has revolutionized the treatment of blood cancers. While the technique has successfully sent patients with advanced disease into remission, it is far from perfect. CAR-T […]
Tags: #CAR T-cell therapy, #Dr. Hong Qin, #Dr. Saad Kenderian, #Mayo Clinic Center for Regenerative Medicine, #regenerative immunotherapy